Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2Terminated 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Sarcoma 1

Conditions

Glioblastoma 2Oligodendroglioma 1Gliosarcoma 1Glioma 1Central Nervous System Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

Cyclophosphamide 1499Cisplatin 1436Paclitaxel 1342Radiotherapy 1310Carboplatin 1267Gemcitabine 1226Docetaxel 1135Bevacizumab 1071Fluorouracil 907Doxorubicin 805Dexamethasone 755Rituximab 745Capecitabine 736Oxaliplatin 710pembrolizumab 700Etoposide 679Irinotecan 641Filgrastim 624Nivolumab 588Cytarabine 587Leucovorin 583Vincristine 517Cetuximab 479Prednisone 478Bortezomib 474Trastuzumab 468Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 444Lenalidomide 437

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × talampanel × Clear all
NCT00267592 2016-05-19

Safety and Efficacy of Talampanel in Glioblastoma Multiforme

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Completed
72 enrolled
CNS

Glioblastoma

NCT00064363 2012-03-08

Talampanel in Treating Patients With Recurrent High-Grade Glioma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡